Table 2.
Clinical products produced using ionizable nanocarriers
| Ionizable nanomaterials | Nucleic acid | Application | Product | Clinical Phase |
|---|---|---|---|---|
| SM-102 | mRNA | COVID-19 vaccine | Spikevax® | Approved in 2021 |
| Acuitas ALC-0315 | mRNA | COVID-19 vaccine | Comirnaty® | Approved in 2021 |
| MC3 | siRNA | ATTR | Onpattro® | Approved in 2018 |
| ALC-0315 | mRNA | COVID-19 vaccine | CVnCoV | III |
| A9 | mRNA | COVID-19 vaccine | LNP-nCo VsaRNA | I |
| CL1 | mRNA | COVID-19 vaccine | ChulaCov19 | I |
| ATX | mRNA | COVID-19 vaccine |
LUNAR-COV19 (ARCT-021) |
III |
| - | mRNA | COVID-19 vaccine | ARCoV | III |
| COVID-19 vaccine | PTX-COVID19B | II | ||
| ATX | mRNA |
Ornithine transcarbamylase deficiency |
LUNAR-OTC (ARCT-810) |
II |
| Cystic fibrosis |
LUNAR-CF (ARCT-032) |
Preclinical | ||
| Influenza | LUNAR-FLU | Preclinical | ||
| Hemophilia B | LUNAR® | Preclinical | ||
| LPO1 | sgRNA | ATTR | NTLA-2001 | I |
SM-102 Heptadecan-9-yl 8-[(2-hydroxyethyl)(6-oxo-6-(undecyloxy) hexyl) amino] octanoate, MC3 (6Z,9Z,28Z,31Z)heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate, ALC-0315 6-[(2-hexyldecanoyl)oxy]-N-{6-[(2-hexyldecanoyl)oxy]hexyl}-N-(4-hydroxybutyl)hexan-1-aminium, COVID-19 coronavirus disease 2019, ATTR transthyretinamyloidosis, mRNA messenger RNA, sgRNA small guide RNA